Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1981 Nov;44(5):670–674. doi: 10.1038/bjc.1981.252

Breast cancer: a comparison of response to endocrine therapy and oestrogen excretion patterns including unusual metabolites.

L Castagnetta, C D'Agostino, M Lo Casto, A Traina, R E Leake
PMCID: PMC2010836  PMID: 6274375

Abstract

The urinary excretion patterns of oestrogen metabolites, including unusual metabolites, were determined by gas chromatography and mass spectrometry for 63 women with advanced breast cancer and 39 normal postmenopausal women. The concentration of total unusual metabolites excreted was found to be an excellent discriminant between breast-cancer patients and controls (P less than 0.0001). Discrimination between responders and non-responders to endocrine therapy was attempted, using several different indices. Of these, the ratio of Classical Oestrogens to Unusual Metabolites (CE/UM) proved a fair discriminant, but the product of this ratio and the oestriol ratio (CE/UM x E3R) was much the best discriminant. This product, termed a Pattern Index, has considerable potential, not only as a discriminant for selecting therapy, but also as a rapid index of patient response to that therapy.

Full text

PDF
670

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BULBROOK R. D., GREENWOOD F. C., HAYWARD J. L. Selection of breast-cancer patients for adrenalectomy or hypophysectomy by determination of urinary 17-hydroxycorticosteroids and aetiocholanolone. Lancet. 1960 May 28;1(7135):1154–1157. doi: 10.1016/s0140-6736(60)91040-0. [DOI] [PubMed] [Google Scholar]
  2. Bishop H. M., Blamey R. W., Elston C. W., Haybittle J. L., Nicholson R. I., Griffiths K. Relationship of oestrogen-receptor status to survival in breast cancer. Lancet. 1979 Aug 11;2(8137):283–284. doi: 10.1016/s0140-6736(79)90295-2. [DOI] [PubMed] [Google Scholar]
  3. Bulbrook R. D., Hayward J. L., Spicer C. C. Relation between urinary androgen and corticoid excretion and subsequent breast cancer. Lancet. 1971 Aug 21;2(7721):395–398. doi: 10.1016/s0140-6736(71)90113-9. [DOI] [PubMed] [Google Scholar]
  4. Dao T. L. Metabolism of estrogens in breast cancer. Biochim Biophys Acta. 1979 Dec 19;560(4):397–426. doi: 10.1016/0304-419x(79)90011-8. [DOI] [PubMed] [Google Scholar]
  5. Edwards D. P., Chamness G. C., McGuire W. L. Estrogen and progesterone receptor proteins in breast cancer. Biochim Biophys Acta. 1979 Dec 19;560(4):457–486. doi: 10.1016/0304-419x(79)90013-1. [DOI] [PubMed] [Google Scholar]
  6. Fishman J., Boyar R. M., Hellman L. Influence of body weight on estradiol metabolism in young women. J Clin Endocrinol Metab. 1975 Nov;41(5):989–991. doi: 10.1210/jcem-41-5-989. [DOI] [PubMed] [Google Scholar]
  7. Hawkins R. A., Roberts M. M., Forrest A. P. Oestrogen receptors and breast cancer: current status. Br J Surg. 1980 Mar;67(3):153–169. doi: 10.1002/bjs.1800670302. [DOI] [PubMed] [Google Scholar]
  8. Knight W. A., Livingston R. B., Gregory E. J., McGuire W. L. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 1977 Dec;37(12):4669–4671. [PubMed] [Google Scholar]
  9. Kodama M., Kodama T. Hormonal status of breast cancer. I. Thoretical basis for the analysis of steroid profile. J Natl Cancer Inst. 1975 May;54(5):1023–1029. [PubMed] [Google Scholar]
  10. Leake R. E., Laing L., Calman K. C., Macbeth F. R., Crawford D., Smith D. C. Oestrogen-receptor status and endocrine therapy of breast cancer: response rates and status stability. Br J Cancer. 1981 Jan;43(1):59–66. doi: 10.1038/bjc.1981.8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Leake R. E., Laing L., McArdle C., Smith D. C. Soluble and nuclear oestrogen receptor status in human breast cancer in relation to prognosis. Br J Cancer. 1981 Jan;43(1):67–71. doi: 10.1038/bjc.1981.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lemon H. M., Wotiz H. H., Parsons L., Mozden P. J. Reduced estriol excretion in patients with breast cancer prior to endocrine therapy. JAMA. 1966 Jun 27;196(13):1128–1136. [PubMed] [Google Scholar]
  13. MacMahon B., Cole P., Brown J. B., Aoki K., Lin T. M., Morgan R. W., Woo N. Oestrogen profiles of Asian and North American women. Lancet. 1971 Oct 23;2(7730):900–902. doi: 10.1016/s0140-6736(71)92504-9. [DOI] [PubMed] [Google Scholar]
  14. Martucci C., Fishman J. Uterine estrogen receptor binding of catecholestrogens and of estetrol (1,3,5(10)-estratriene-3,15alpha,16alpha,17beta-tetrol). Steroids. 1976 Mar;27(3):325–333. doi: 10.1016/0039-128x(76)90054-4. [DOI] [PubMed] [Google Scholar]
  15. Nimrod A., Ryan K. J. Aromatization of androgens by human abdominal and breast fat tissue. J Clin Endocrinol Metab. 1975 Mar;40(3):367–372. doi: 10.1210/jcem-40-3-367. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES